Erythroplasia of Queyrat: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 3: | Line 3: | ||
{{CMG}} {{AE}} {{Ammu}} | {{CMG}} {{AE}} {{Ammu}} | ||
{{SK}} | {{SK}} EQ | ||
==Overview== | ==Overview== | ||
==Historical Perspective== | ==Historical Perspective== | ||
*Erythroplasia of Queyrat was named after Louis Queyrat, a French dermatologist who was head of the dermatology service of l'Hôpital Ricord, a venereal hospital in Paris, now Hôpital Cochin. | *Erythroplasia of Queyrat was named after Louis Queyrat, a French dermatologist who was head of the dermatology service of l'Hôpital Ricord, a venereal hospital in Paris, now Hôpital Cochin. | ||
==Pathophysiology== | ==Pathophysiology== | ||
*The pathogenesis of Erythroplasia of Queyrat is characterized by [[squamous cell carcinoma]] in situ of the [[glans penis]]<ref name="Lookingbill">Marks, James G; Miller, Jeffery (2006). ''Lookingbill and Marks' Principles of Dermatology'' (4th ed.). Elsevier Inc. Page 63. ISBN 1-4160-3185-5.</ref> | *The pathogenesis of Erythroplasia of Queyrat is characterized by [[squamous cell carcinoma]] in situ of the [[glans penis]]<ref name="Lookingbill">Marks, James G; Miller, Jeffery (2006). ''Lookingbill and Marks' Principles of Dermatology'' (4th ed.). Elsevier Inc. Page 63. ISBN 1-4160-3185-5.</ref> | ||
*The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway | microscopic h*The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Age=== | ===Age=== | ||
*Erythroplasia of Queyrat is more commonly observed among patients aged 40 years old. | *Erythroplasia of Queyrat is more commonly observed among patients aged 40 years old. | ||
===Gender=== | ===Gender=== | ||
*Males areaffected with Erythroplasia of Queyrat. | *Males areaffected with Erythroplasia of Queyrat. | ||
==Risk Factors== | ==Risk Factors== | ||
*Most common risk factor in the development of Erythroplasia of Queyrat are uncircumcised penis. | *Most common risk factor in the development of Erythroplasia of Queyrat are uncircumcised penis. | ||
== Diagnosis == | == Diagnosis == | ||
=== Symptoms === | === Symptoms === | ||
*Symptoms of Erythroplasia of Queyrat may include the following: | *Symptoms of Erythroplasia of Queyrat may include the following: | ||
:*Red rash on the tip of the penis | :*Red rash on the tip of the penis | ||
:*Irritation on the tip of the penis | :*Irritation on the tip of the penis | ||
===Imaging Findings=== | ===Imaging Findings=== | ||
*There are no | *There are no imaging study findings associated with Erythroplasia of Queyrat. | ||
== Treatment == | == Treatment == | ||
=== Medical Therapy === | === Medical Therapy === | ||
*The mainstay of therapy for Erythroplasia of Queyrat is imiquimod or 5-fluorouracil for several weeks to months. | *The mainstay of therapy for Erythroplasia of Queyrat is imiquimod or 5-fluorouracil for several weeks to months. | ||
=== Surgery === | === Surgery === | ||
*Microscopic shaving (Mohs surgery) can be performed for patients with aggressive forms of Erythroplasia of Queyrat. | *Microscopic shaving (Mohs surgery) can be performed for patients with aggressive forms of Erythroplasia of Queyrat. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category: | [[Category:Oncology]] | ||
Revision as of 19:14, 14 April 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]
Synonyms and keywords: EQ
Overview
Historical Perspective
- Erythroplasia of Queyrat was named after Louis Queyrat, a French dermatologist who was head of the dermatology service of l'Hôpital Ricord, a venereal hospital in Paris, now Hôpital Cochin.
Pathophysiology
- The pathogenesis of Erythroplasia of Queyrat is characterized by squamous cell carcinoma in situ of the glans penis[1]
microscopic h*The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway
Epidemiology and Demographics
Age
- Erythroplasia of Queyrat is more commonly observed among patients aged 40 years old.
Gender
- Males areaffected with Erythroplasia of Queyrat.
Risk Factors
- Most common risk factor in the development of Erythroplasia of Queyrat are uncircumcised penis.
Diagnosis
Symptoms
- Symptoms of Erythroplasia of Queyrat may include the following:
- Red rash on the tip of the penis
- Irritation on the tip of the penis
Imaging Findings
- There are no imaging study findings associated with Erythroplasia of Queyrat.
Treatment
Medical Therapy
- The mainstay of therapy for Erythroplasia of Queyrat is imiquimod or 5-fluorouracil for several weeks to months.
Surgery
- Microscopic shaving (Mohs surgery) can be performed for patients with aggressive forms of Erythroplasia of Queyrat.
References
- ↑ Marks, James G; Miller, Jeffery (2006). Lookingbill and Marks' Principles of Dermatology (4th ed.). Elsevier Inc. Page 63. ISBN 1-4160-3185-5.